pembrolizumab
merck
['sclc', 'nsclc', 'improve']
ct+io vs io alone in pd-l1 &gt;50% nsclc:
1)indirect comparison kn024 and kn189 equal mos and 3-y os (44%)
2)rwd, no differences in pfs &amp; os
3)fda ma not os improvement, only improves pfs (exploratory)
4)pending persee trial,
but in daily practice some may benefit of combo #asco2022 
Medical Oncologist - Thoracic tumors. Personalized treatment approches @EORTC